tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

GLUE Stock Latest News

5 Stocks that Analysts Love in March 2024
Market News5 Stocks that Analysts Love in March 2024
1M ago
GSK
ANAB
Monte Rosa Therapeutics Unveils Corporate Strategy Presentation
PremiumCompany Announcements
Monte Rosa Therapeutics Unveils Corporate Strategy Presentation
1M ago
8K
GLUE
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
1M ago
GLUE
Monte Rosa Therapeutics announces anticipated upcoming milestones
PremiumThe Fly
Monte Rosa Therapeutics announces anticipated upcoming milestones
1M ago
GLUE
Monte Rosa Therapeutics expects cash to fund operations into 1H26
PremiumThe Fly
Monte Rosa Therapeutics expects cash to fund operations into 1H26
1M ago
GLUE
Monte Rosa Therapeutics reports Q4 EPS (58c), consensus (33c)
PremiumThe FlyMonte Rosa Therapeutics reports Q4 EPS (58c), consensus (33c)
1M ago
GLUE
Monte Rosa Therapeutics initiates IND-enabling studies for MRT-8102
PremiumThe Fly
Monte Rosa Therapeutics initiates IND-enabling studies for MRT-8102
1M ago
GLUE
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
PremiumPress Releases
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
1M ago
GLUE
Wedbush starts Monte Rosa at Outperform on ‘highly differentiated’ programs
PremiumThe Fly
Wedbush starts Monte Rosa at Outperform on ‘highly differentiated’ programs
2M ago
GLUE
Monte Rosa Therapeutics initiated with an Outperform at Wedbush
PremiumThe Fly
Monte Rosa Therapeutics initiated with an Outperform at Wedbush
2M ago
GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
PremiumPress Releases
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
3M ago
GLUE
Monte Rosa Therapeutics provides updates, milestones for 2024
PremiumThe Fly
Monte Rosa Therapeutics provides updates, milestones for 2024
3M ago
GLUE
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
PremiumPress ReleasesMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
3M ago
GLUE
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
5M ago
GLUE
Monte Rosa Therapeutics reports Q3 EPS (70c), consensus (72c)
PremiumThe Fly
Monte Rosa Therapeutics reports Q3 EPS (70c), consensus (72c)
5M ago
GLUE
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
PremiumPress Releases
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
5M ago
GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
PremiumPress Releases
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
6M ago
GLUE
Monte Rosa Therapeutics announces $25M registered direct offering
PremiumThe Fly
Monte Rosa Therapeutics announces $25M registered direct offering
6M ago
GLUE
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
PremiumPress Releases
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
6M ago
GLUE
Monte Rosa Therapeutics price target lowered to $11 from $31 at JPMorgan
PremiumThe FlyMonte Rosa Therapeutics price target lowered to $11 from $31 at JPMorgan
6M ago
GLUE
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
PremiumPress Releases
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
6M ago
GLUE
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
PremiumPress Releases
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
6M ago
GLUE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >